cancer vaccine

Scancell picks winner from phase 2 cancer vaccine face-off

Scancell linked iSCIB1+ to a 69% response rate in advanced melanoma, leading the biotech to pick the next-generation candidate over its older sibling.

Nick Paul Taylor Jul 22, 2025 9:38am

layoffs job cuts fired exit restructuring layoff reduction

BioNTech's chief strategy officer heads for the exit

Jul 17, 2025 10:55am

medical data concept with hospital in the background

OSE shares 65% OS rate behind cancer vaccine's phase 2 win

Jun 3, 2025 7:05am

Apollomics tags out of TYG oncology pact to cut costs

Apr 4, 2025 6:45am

Otsuka gives cancer candidates the kiss-off on strategic grounds

Feb 14, 2025 5:30am

Updated photo of exterior of Dana-Farber Cancer Institute

Cancer vaccine prevents kidney cancer comeback in small trial

Feb 6, 2025 3:00pm